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Abstract 1 
Background 2 
Countries with similar health systems but different medicines policies might result in 3 
substantial medicines usage differences and resultant outcomes. The literature is sparse in this 4 
area. 5 
Objective 6 
To review pharmaceutical policy research in New Zealand and Australia and discuss 7 
differences between the two countries and the impact these differences may have on 8 
subsequent medicine access. 9 
 10 
Methods  11 
A review of the literature (2008 to 2016) was performed to identify relevant, peer-reviewed 12 
articles. Systematic searches were conducted across the six databases MEDLINE, PubMed, 13 
Science Direct, Springer Links, Scopus and Google Scholar. A further search of journals of 14 
high relevance was also conducted. Using content analysis, a narrative synthesis of 15 
pharmaceutical policy research influencing access to medicines in Australia and New 16 
Zealand was conducted. The results were critically assessed in the context of policy material 17 
available via grey literature from the respective countries.  18 
 19 
Results 20 
Key elements regarding pharmaceutical policy were identified from the 35 research papers 21 
identified for this review. Through a content analysis, three broad categories of 22 
pharmaceutical policy were found, which potentially could influence patient access to 23 
medicines in each country; the national health system, pricing and reimbursement. Within 24 
these three categories, 9 subcategories were identified: national health policy, pharmacy 25 
system, marketing authorization and regulation, prescription to non-prescription medicine 26 
switch, orphan drug policies, generic medicine substitution, national pharmaceutical schedule 27 
and health technology assessment, patient co-payment and managed entry agreements.  28 
 29 
Conclusions 30 
This review systematically evaluated the current literature and identified key areas of 31 
difference in policy between Australia and NZ. Australia appears to cover and reimburse a 32 
greater number of medicines, while New Zealand achieves much lower prices for medicines 33 
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than their Australian counterparts and has been more successful in controlling national 34 
pharmaceutical expenditure. Delays in patient access to new therapies in New Zealand have 35 
considerable implications for overall patient access to medicines; however, higher patient co-36 
payments and relative pharmaceutical expenditure in Australia and its effect upon patient 37 
access to medicines must also be considered.   38 
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Introduction 39 
Pharmaceutical policy has been defined as the branch of health policy that “deals with the 40 
principles guiding decision making in the field of pharmaceuticals”,1 with the aim of 41 
contributing towards the overall health and wellbeing in a given society within a healthcare 42 
system. Pharmaceutical policy is varied and includes licensing, pricing, formulatory 43 
management, prescribing, pharmacy services, rational drug usage, pharmaceutical economics, 44 
access and affordability of medicines. The overall objectives of pharmaceutical policy 45 
involve maximising of access to medicines and ensuring the quality of medicinal products, 46 
whilst controlling the cost of health care and medicine and promoting rational drug use.
2
  47 
Currently, medicines are the most common form of medical intervention and within 48 
Organisation for Economic Cooperation and Development (OECD) countries pharmaceutical 49 
expenditure ranges from 8-29% of healthcare spending.
3-6
 However, medicines can be 50 
expensive and cost can act as a barrier to medicine access. Constraints in medicines access 51 
have important implications for patients regarding morbidity and mortality,
3
 and thus this is 52 
an important topic of discussion amongst policy decision-makers in countries worldwide.  53 
Healthcare costs have increased significantly over the past few decades and have been 54 
reported as “unsustainable” in advanced economies, without suitable reform. Both health and 55 
finance ministries need to work together to reach an optimal outcome for the budget and 56 
patient health.  57 
Two countries that are renowned for minimising their cost increases are New Zealand and 58 
Australia, and thus it is important to compare and contrast their health policies and the 59 
subsequent effect on medicines access.  60 
In New Zealand, the agency responsible for the decision on drug safety, registration and 61 
regulation in the country is the New Zealand Medicines and Medical Devices Safety 62 
Authority (Medsafe).  A separate and independent authority that manages the pharmaceutical 63 
budget is the Pharmaceutical Management Agency (PHARMAC). PHARMAC oversee the 64 
reimbursement and purchasing of pharmaceuticals and medical devices for the community, as 65 
well as help the district health board’s (DHB’s) assess and procure the medicines and medical 66 
devices used in public hospitals.
3,4
 Additionally, they maintain the country’s national 67 
pharmaceutical schedule and negotiate the national prices for new medicines.
3
 This schedule 68 
represents the partly or fully subsidised medicines for New Zealand from the national 69 
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pharmaceutical budget and includes both medicines available from practitioners by 70 
prescription in hospitals or in the community.
3
 PHARMAC use a capped budget, which has 71 
proven of international interest, but also has been a source of considerable debate, as this may 72 
impact on access to medicines, in particular new subsidised medicines.
4
 73 
 In Australia the registration of all medicines is evaluated by the Australian Therapeutic 74 
Goods Administration (TGA).
5
 The Pharmaceutical Benefits Advisory Committee (PBAC), 75 
established under the National Health Act 1953, is an independent body appointed by the 76 
Australian government. PBAC assesses applications for each medicine regarding both 77 
clinical and cost-effectiveness for a particular indication (s) (see current revised PBAC 78 
guidelines 5.0).
7
 Once a positive recommendation is made, the ultimate decision is made by 79 
the Minister of Health. Price negotiations may then be made by the Australian Department of 80 
Health.
3,4,8
 Pharmaceuticals that are subsidised by the Australian Federal Government are 81 
then listed in the Pharmaceutical Benefits Scheme (PBS),
3,4
 managed by the Australian 82 
Department of Health, under the Australian National Health Act 1953.
4
 Expenditure under 83 
the PBS in not capped, to allow for new medicines to be added to the schedule, however, if a 84 
pharmaceutical will cost over $20 million per year, the decision is referred to Cabinet for 85 
approval within the set health budget.  86 
While both PHARMAC and PBAC consider cost-effectiveness, budget impact, utilise rebates 87 
and have risk-sharing agreements, PHARMAC is unique as it operates within a capped 88 
budget.
3-5
 New medicines in NZ can only be added to the pharmaceutical schedule if the 89 
budget allows.
4,5
 This is not the case in Australia where the Australian PBS does not operate 90 
within a defined funding envelope,
4,5
 but under a total health budget.  91 
Distinct differences exist between the two countries. These differences include the ability to 92 
negotiate independently, for example, PHARMAC is actively involved in bundling deals for 93 
several medicines as well as tendering contracts with single sponsors.
4,5
  Policies at a patient 94 
level also exist, such as risk sharing and managed entry agreements with suppliers, the extent 95 
of co-payments and concessions for various population groups as well as medications 96 
available ‘on’ and ‘off’ prescription all have the capacity to influence patient access to 97 
medicines.
5,6
   98 
The aim of this paper is to critically assess, review and document the status of pharmaceutical 99 
policy research in New Zealand and Australia and the impact of respective policies at the 100 
patient-level.  101 
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Specifically, the objectives were to: (i) compare medicines policy in Australia and New 102 
Zealand and how these differences impact on patient access to medicines and (ii) to make 103 
recommendations for future policy decision-makers to consider when considering medicines 104 
policy reform.  105 
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Methods 106 
Defining Access 107 
The definition of access to medicines can be varied amongst the literature. Access to 108 
medicine considers the listing of a medicine on the country’s pharmaceutical schedule and 109 
also the ability of an individual, both financially and physically, to obtain and receive 110 
relevant care involving the respective medicine.
3,10
 Access has also commonly been linked to 111 
medicine availability which is defined as whether a drug has obtained a relevant marketing 112 
authorization and registration under the relevant authority for drug safety, registration and 113 
regulation in the country.
10,11
  114 
This study refers to outcomes that affect medicine access which encompass both the 115 
availability and access to medicines. Therefore, for the purposes of this study access to a 116 
medicine includes policies or factors that affect the availability of a medicine as well those 117 
that enable an individual (financially and physically) to obtain and receive relevant care 118 
involving the respective medicine. 119 
Search Strategy 120 
The PRISMA guidelines for conducting systematic reviews were followed,
9
 – Appendix 1. 121 
This study used systematic searches between August 1st, 2015 and 1
st
 July 2016 to identify 122 
peer-reviewed articles published between 2008 and July 2016.  The search strategy was 123 
purposefully designed to be broad, in order to ensure all relevant material was included. The 124 
databases searched included: Medline, PubMed, Google Scholar, Springer Links, Science 125 
Direct and Scopus. The following relevant journals were also searched to ensure 126 
completeness for the same time period: PLoS One, PLoS Medicine, Nature, Health Policy, 127 
Pharmaeconomics, Medical Journal of Australia and the New Zealand Medical Journal. Our 128 
search included both mapped and un-mapped terms which are illustrated in Figure 1. 129 
Keywords included the following: (“Access” or “Availability” or “Accessibility”) and 130 
(“Pricing” or “Funding” or Reimbursement”) and (“Medicines” or “Drugs” or 131 
“Pharmaceuticals”) and (“Regulation” or “Policy”) and (“New Zealand” or “Australia”). The 132 
keywords were combined and integrated in database and journal searches. Within the 133 
conducted search “Boolean Operator” rules were utilised. The terms used were searched 134 
using ‘AND’ to combine the keywords listed and using ‘OR’ to remove search duplication 135 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
7 
 
where possible. Reference lists of the retrieved articles were assessed for relevant articles that 136 
our searches may have missed. The process of identification, screening and inclusion of 137 
papers for this review is detailed in PRISMA format in Figure 1. 138 
Study Selection 139 
Inclusion criteria were formulated that reflected the research aim. Firstly, papers were 140 
included if they referred to medicines policy and were investigating political and regulatory 141 
mechanisms in Australia and New Zealand by which medicines are accessed, funded and 142 
reimbursed and the mechanisms that define these aspects of pharmaceutical policy and 143 
medicine access. In addition, the studies must report outcomes in relation to patient access to 144 
medicines. Studies were excluded if not written in English or those in which the authors were 145 
unable to retrieve a full-text version of the study. It included original articles, reviews, 146 
commentaries and opinions if they described access, funding and reimbursement of 147 
medicines in New Zealand and Australia. It also excluded any studies that did not report 148 
policies or outcomes related to Australia or New Zealand. Inclusion and exclusion criteria are 149 
detailed in full in Table 1. 150 
** Insert Table 1 ** 151 
Data extraction 152 
Study characteristics were extracted from all relevant studies and were recorded in an 153 
extraction table. One researcher (TG) compared and extracted data and discussed any 154 
discrepancies with other researchers (ZB, AS) when this was required. An overview of the 155 
identification process is documented in Figure 1.   156 
Analysis  157 
Narrative synthesis of the articles was undertaken to compare policies and outcomes between 158 
the two countries. Themes and sub-themes were drawn from the data, until no more themes 159 
and sub-themes could be identified, and all important and differing policy areas with respect 160 
to access to medicines between Australian and New Zealand were considered. Through this 161 
analysis identification of how differing policies could have impact on patient access to 162 
pharmaceuticals were established.  163 
 164 
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Results  166 
Screening, selection and included studies 167 
A diagrammatic depiction of the search strategy is included in Figure 1. The searches across 168 
all databases and journals identified 10,900 titles. The titles and abstracts of all retrieved 169 
articles were reviewed by TG for relevance. Studies were excluded if they did not meet the 170 
inclusion/exclusion criteria specified in the study. After removing duplicates and 171 
titles/abstracts unrelated to access to medicines in Australia or New Zealand, we identified 172 
(n=230) peer-reviewed articles for further review.  173 
Sixty-three articles were relevant to access, funding and reimbursement of medicines in New 174 
Zealand and Australia and were considered against the inclusion/exclusion criteria of this 175 
review. A total of 30 articles were excluded at this stage. Two further studies were identified 176 
from the reference lists of the retrieved articles. The final number of articles therefore 177 
included for analysis in this review was 35 (Figure 1). 178 
**Insert Figure 1** 179 
Data collection and analysis  180 
The data extracted from the 35 articles was documented; these articles generated three major 181 
themes with 9 major sub-themes; these are detailed in Table 2. The themes included: the 182 
national health system which was sub divided into five major sub-themes; national health 183 
policy, pharmacy system, marketing authorisation and regulation, prescription to non-184 
prescription medicine switch and orphan drug policies. The second major theme was pricing; 185 
this included the sub-theme of generic medicine substitution. The final major theme was 186 
reimbursement; sub-themes included the national pharmaceutical schedule and health 187 
technology assessment, patient co-payments and managed entry agreements. Each theme and 188 
sub-theme is now described in more detail, with comparisons between Australian and New 189 
Zealand research. 190 
These themes need to be considered within the context of the policies of each country and 191 
therefore an overview of these policies has been detailed in Table 3. 192 
**Insert Table 2 and 3 ** 193 
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1. National Health System  194 
The five sub-themes identified within the national health system theme include the national 195 
health policy, pharmacy system, marketing authorization and regulation, prescription to non-196 
prescription medicine switch and orphan drug policies.  197 
i. National Health Policy 198 
Both Australia and New Zealand have a publically funded health system, alongside a private 199 
hospital sector.
12,13
 In Australia, the national government funds two thirds of total healthcare 200 
spending while the other third is funded by other, lower levels of the national and state 201 
government.
4,5,12
  In New Zealand 80% of expenditure on health care is publically funded, 202 
and 20 District Health Boards across New Zealand are responsible for the public health 203 
services in their respective populations.
4,5,13
 The regulation and funding of medicines in 204 
Australia is determined by the National Medicines policy. This policy has the overall aim to 205 
‘meet medication and related service needs so that optimal health outcomes and economic 206 
objectives are achieved’.12 This policy has four key objectives to; ensure medicines meet a 207 
standard of safety, quality and efficacy, ensure timely access to necessary medicines at an 208 
affordable cost to the individual and the Australian community and ensure the quality use of 209 
medicines and the maintenance and regulation of the Australian medicines industry.
12
 In New 210 
Zealand ‘Medicines New Zealand’ provides a framework document to determine the 211 
direction for agencies and stakeholders in the New Zealand medicines sector. It aims to; 212 
‘deliver equitable access to safe quality medicines used in the most effective ways possible’, 213 
promote a transparent, accessible and trusted medicine sector and to deliver affordable 214 
medicines that meet the needs of New Zealander’s and is sustainable.4,5,13 Medicines policy in 215 
New Zealand includes the pharmaceutical subsidy card (allowing prescriptions to be filled at 216 
reduced or no cost), high use health cards, community services cards (for lower income 217 
families), disability allowances and coverage by the accident compensation cooperation 218 
(ACC) in the case of an accident which requires use of medicines.
4,5,13
   219 
Patients have access to medicines in both countries through community pharmacies and 220 
hospitals, as thus we must consider both critical elements when evaluating access to 221 
medicines for patients.
4,5,12,13
  222 
ii The Pharmacy System 223 
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The pharmacy system in both Australia and New Zealand primarily provide dispensing 224 
services for prescription-only medicines, as well as providing a range of over-the-counter 225 
medicines and patient-related services including, the provision of health-related information, 226 
medications management, preventative care and/or clinical interventions.
4,5,12,13
   227 
There are over 6, 663 pharmacies and chemists throughout Australia,
14
 with pharmacy 228 
ownership restricted to registered pharmacists. Additional programmes to improve access and 229 
use of medicines have been established; medication adherence, medication management, 230 
rural support as well as Aboriginal and Torres Strait Islander programs have been developed 231 
and implemented in Australia with the aim to improve access to medicines as well as support 232 
quality community pharmacy services. The programs often include allowances to approved 233 
pharmacies delivering and distributing medicines subsidised on the PBS.
15
 In December 2015 234 
the DOH stated that under the Sixth Community Pharmacy Agreement there would be up to 235 
$1.6 billion in funding available, consisting of $613 million for the continuation of programs 236 
and services from the fifth CPA, $50 million for a new pharmacy trial program and up to 237 
$600 million for new and expanded programs.
16
 238 
In New Zealand, there are close to 1000 community pharmacies,
17
 distributed across the 239 
country. The pharmacies tend to operate under contractual relationships with district health 240 
boards and receive funding for providing particular services to patients, most notably the 241 
long-term conditions (LTC) service and services for primary healthcare. The LTC service 242 
provides support to patients who have at least one long-term health condition, who have been 243 
identified as having issues with medication adherence. The aim is for these patients to 244 
become self-managing with their medications.
18
 The pharmacy self-care programme which is 245 
a health education programme delivered through pharmacies.
13
 The latter programme aims to 246 
improve access to medicines and promote the quality of medicines using pharmacies as 247 
primary health care centres.
6,13
 It consists of online training modules for pharmacists and 248 
pharmacy staff and uses ‘fact cards’ as resources for patients. Together these provide relevant 249 
and critical information and support patient consultations.
6,13 
250 
iii. Marketing Authorization and Regulation 251 
Marketing authorisation and regulation involves the assessment of a medicine, by the relevant 252 
regulatory authority, before the medicine is authorised for marketing and subsidy evaluation.  253 
This is a critical step in enhancing the availability (and access) of medicines.
4,5,10,12,13,15,19,20
 254 
This process generally includes substantial scientific evaluation of the benefits and risks of 255 
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medicines to determine whether the drug is safe for use and for a specific indication(s) 
5,20
. In 256 
Australia, the Therapeutic Goods Administration (TGA) evaluates applications for the 257 
registration of new medicines and indications and ensures the acceptable quality, safety and 258 
efficacy of new medicines and/or indications.
3,4,12
 Where medicines meet these standards, 259 
they are included on the Australian Register of Therapeutic Goods.
12
 In Australia, parallel 260 
processing of medicines is possible; in contrast this is not the case in New Zealand.
3,4,5,12,30
 261 
Parallel processing allows submission to the TGA for medicine registration to be conducted 262 
at the same time as submission to the Pharmaceutical Benefits Advisory Committee (PBAC), 263 
who provide a clinical and economic evaluation, and subsequent recommendation to the 264 
Minister of Health regarding whether it should be listed in the Pharmaceutical Benefits 265 
Scheme (PBS).
3,4,30 
The risk associated with parallel processing in Australia is offset by cost-266 
recovery fees paid by the sponsor company to cover ‘resources specific to the subsidised 267 
access evaluation’ and ‘agreement that the outcome of the assessment by the subsidised 268 
access agency will not be made publically available until the regulatory agency has made a 269 
decision’.5 In New Zealand, Medsafe is responsible for applications for registration and 270 
marketing of new medicines in the country.
3,4,5,13
 Medsafe, in a similar manner to the 271 
Australian TGA, considers the efficacy, safety and quality of medicines both through pre-272 
marketing evaluation and post-marketing monitoring.
3,4,5,13
  273 
Both countries estimate to have a registration period of 52 weeks, however, Australia had a 274 
shorter duration from regulatory submission to subsidised access of 72 weeks compared with 275 
84 weeks in New Zealand.
5
 This difference was most likely reflective of parallel processing 276 
in Australia.
5
 Parallel (regulatory) processing has been acknowledged to potentially enable 277 
‘time efficiencies to be gained’.5 Ragupathy et al.,30 considered the age of entities licensed 278 
(registered) across four countries (United States of America, United Kingdom, Australia and 279 
New Zealand). In comparison, Australia and New Zealand’s entity age differed, with entities 280 
licensed in New Zealand on average being older than those licensed in Australia. The median 281 
age of licensing was 7795 days in Australia and 8936 days in NZ.
30
 Similarly, Cook et al,
5
 282 
found critical differences in the time taken from regulatory submission to subsidised access to 283 
medicines. Another study by Wonder et al
1
 compared the timeliness of availability and access 284 
to medicines between Australia and New Zealand. Of 59 medicines listed in Australia and 285 
New Zealand between 2000 and 2009, registration occurred on average sooner in Australia 286 
than in NZ with a mean difference of 9 months. In particular, 43 of the 59 medicines were 287 
registered in Australia before NZ.
1
 The timely availability of (new) medicines through 288 
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registration and thus approval for marketing has been noted as a critical indication in enabling 289 
downstream access to medicines by many studies.
3,4,5,10,12,13,15,20-29,30
 290 
iv. Prescription to Non-Prescription Medicine Switch 291 
Prescription to non-prescription switch or ‘switch’, also known as reclassification or down 292 
scheduling, is the movement of medicines ‘down’ medicine schedules to facilitate more 293 
convenient and timely access to medicines for patients.
6,19
 Switch has been utilised to enable 294 
self-care, patient-centred care programmes and improving patient access to medicines.
6,19
 295 
Australia and New Zealand both have three medicine schedules; pharmacist- only, 296 
pharmacy-only and general sales.
19
 Australia does not have an overall governmental position 297 
on medicine switch and The Secretary to the Department of Health, or their respective 298 
delegates make the final decision on switch.
6
 In New Zealand the Medicines Classification 299 
Committee (MCC) recommends classifications of medicines.
6
 Gauld et al.,
6
 investigated 300 
factors that both enabled and prevented switch in Australia compared to New Zealand. The 301 
study found that New Zealand was more active in switching medicines from prescription to 302 
non-prescription, with New Zealand approving 13 of 25 medicines for switch between 2000 303 
and 2011, in comparison Australia approving 9 of 22 medicines in the same time period.
6
 304 
Enabling factors for switch to occur were described; in New Zealand enablers included a 305 
small country, pharmacist only schedule, openness to different ideas, industry confidence in 306 
the MCC, confidence in Medsafe, confidence in pharmacy and consumers, ability to advertise 307 
over-the-counter medicines and a potential to influence switch in Australia.
6
 Australia 308 
identified less enabling factors including, pharmacist only schedule, confidence in pharmacy 309 
and consumers.
6
 Barriers to switch were also reported, more were described by Australia; 310 
advertising restrictions, risk adverse committee, immediate generic entry and an inability to 311 
see the regulator were all listed. In New Zealand the major barrier to switch was the 312 
recognition of a low co-payment on prescriptions and immediate generic entry.
6
 A separate 313 
study considered factors affecting ‘switch’;19 barriers to ‘switch’ often appeared to dominate 314 
over enablers. In Australia barriers included ‘committee constitution, individuals, events, 315 
politics, advertising limitations and rigidity’.19 In New Zealand market exclusivity and 316 
transparency, population size and the low co-payment on prescription medicines were key 317 
barriers. Both studies recognised that while ‘switch’ had the capacity to enhance patient 318 
access to medicines in a convenient location, considerations of the safety of these medicines 319 
off-prescription, introduction of generic medicines, low co-payments on prescription 320 
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medicines in New Zealand and a limited market size were considered by relevant committees 321 
in Australia and New Zealand.
6,19
  322 
iv. Orphan Drug Policies 323 
Orphan drugs are medicines or vaccines intended to treat, prevent or diagnose a rare 324 
disease.
10
 Examples of rare diseases include genetic diseases, rare cancers, infectious tropical 325 
diseases and degenerative diseases.
10
 The definition of rare diseases varies across 326 
jurisdictions but typically considers disease prevalence, severity and existence of alternative 327 
therapeutic options.
10
  In Australia, the definition of an Orphan Drug is a condition with a 328 
prevalence of not more than 5 in 10,000 people which is life-threatening or seriously 329 
debilitating condition and no existing therapeutic goods for prevention, diagnosis or treatment 330 
or significant benefit.
10
 331 
The nature of rare diseases means that there are limited numbers of patients who have these 332 
conditions; drug development therefore is also limited and/or access to these medicines can 333 
be difficult, due to high cost and unfavourable cost effectiveness ratios in economic 334 
analyses.
10,11
 Policies and legislation regarding orphan drugs intends to address the challenges 335 
of exorbitant costs of product development and narrow profit potential due to the smaller 336 
market size for each indication. Orphan drug policies aim to enhance both availability and 337 
access of these medicines and includes a variety of incentives to encourage research, 338 
development and marketing as well as pre-licensing access and compassionate use 339 
programmes into treatments for rare diseases.
10,11
  340 
Both Australia and New Zealand recognise rare diseases and orphan drugs. Australia 341 
introduced an orphan drugs act under the amended Therapeutic Goods Act in 1997.
10
 This act 342 
includes independent orphan drug designation and marketing authorization/regulatory 343 
approval with fee reductions for orphan drugs.
10,11
 Under the orphan drugs program there is a 344 
100% fee waiver.
31
 In terms of enhancing availability of these drugs, Australia also has in 345 
place pre-licensing access and regulatory assistance for manufacturers.
10
 Australia 346 
implemented orphan drug policies which look to enhance their access to patients. In 347 
particular, orphan drugs may be considered for subsidisation under Australia’s Life Saving 348 
Drugs Programme (LSDP) for eligible patients, which provides subsidised access to drugs for 349 
rare conditions.
10,11
  350 
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In contrast, New Zealand does not include mention of orphan drugs in legislation. However, 351 
in 2014 PHARMAC aimed to improve access to medications for rare disorders and requested 352 
feedback.
32
. Currently there are ten medicines approved for funding via this pilot scheme; 353 
PHARMAC has reported that it intends to continue to make these medications available.
32
 354 
2. Pricing 355 
There are direct and indirect impacts of pricing on patient access to medicines. Firstly, 356 
regarding subsidised medicines, the price paid will dictate which medicines may be funded 357 
by the government or relevant regulatory agency, and in some cases (i.e. in New Zealand) 358 
this may impact on how many medicines (due to the capped nature of the budget).
3,4,12,13,20
 359 
Price also has a direct impact on patient access to medicines in the case of non-subsidised 360 
(high cost) medicines,
3,4,12,13,20
 as these become out-of-pocket costs for patients.  361 
Both Australia and New Zealand utilise varying degrees of reference and value based pricing. 362 
In Australia, pharmaceutical companies apply for PBS listing following positive approval for 363 
marketing by the TGA (or with parallel processing, simultaneously) and these applications 364 
are evaluated by PBAC.
3,4,12,13,20,21
 Price negotiations may then be made by the Australian 365 
Department of Health.
3,4,8
 Listing of new medicines are generally based upon reference 366 
pricing (cost minimisation), where medicine efficacy and safety are considered relative to 367 
existing listed medicines. An alternative used is value based pricing, where medicines are 368 
recommended for funding if they meet an acceptable incremental cost-effectiveness ratio 369 
(ICER).
3,4,12,13,20,21,33
  370 
In New Zealand, PHARMAC utilise several pricing techniques to fund medicines within their 371 
fixed medicines budget.
3,4,12,13,20,21,33
 These include price negotiations, sole or generic supply 372 
contract tendering, reference pricing for medicines with similar therapeutic effects and price 373 
rebates.
3,4,12,13,20,21,33
 PHARMAC also utilise rebates, expenditure caps (when sales exceed a 374 
set limit the manufacturer will cover some or all of the costs to supply the medicine above 375 
this cap) and cross product agreements (an agreement to subsidise a medicine dependent on a 376 
price reduction on one or a number of medicines already subsidised on the national schedule) 377 
in order to lower the price paid.
33-36
  378 
A stark difference between the Australian and New Zealand pricing and reimbursement 379 
strategies is that PHARMAC’s operates within a capped budget, which is not the case in 380 
Australia. In Australia the total Health Expenditure is capped, however within that the 381 
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proportion is spent by the PBS is not capped, this is to allow for new medicines to be 382 
added.
3,4,5,23
 Morgan et al.,
20
 investigated basic pharmaceutical policy structures and 383 
performance indicators for the seven difference countries, including Australia and New 384 
Zealand, and discovered that the growth rate for pharmaceutical expenditure in relation to 385 
health care expenditure and national income from 1995 to 2005 was the lowest in New 386 
Zealand (2.5% per annum) compared to all countries in the study while Australia had a 387 
growth rate of 6.3% per annum.
20
 It is acknowledged that this slow rate of growth may reflect 388 
the use of a capped budget in the operation of the New Zealand national pharmaceutical 389 
schedule.
20
  A 2011 study by Spinks et al.,
33
 compares medicine prices for many select drugs 390 
from Australia and New Zealand. New Zealand attained lower prices for 29 of the 34 drugs 391 
included in the study with a saving of AU $0.93 billion if purchased at the New Zealand 392 
price.
33
 It is noted that a more effective use of competition and a competitive tender process 393 
in the purchasing of medicines by New Zealand and its PHARMAC may be the critical factor 394 
in the differences in prices paid for medicines.
33
 Interestingly, an analysis of medicine prices 395 
in New Zealand compared to 16 European countries found that New Zealand prices were 396 
found in the lowest quartile for five medicines and in the highest quartile for seven other 397 
products for a basket of 14 medicines.
34
 Analysis of these results highlighted that the lower 398 
priced were medicines that had a generic alternative available. All medicines in the study 399 
were reimbursed in New Zealand so this difference was recognised to likely be due to New 400 
Zealand’s success in possessing lower prices for generic products as well as uncertainty on 401 
the ‘real price’ paid due to PHARMAC’s desire to release the listed price alone and not the 402 
true price paid (and discount negotiated) for the agency to contain pharmaceutical 403 
expenditure.
34
   404 
Generic Medicine Substitution 405 
Generic medicines are defined by the World Health Organisation (WHO) as “a 406 
pharmaceutical product, usually intended to be interchangeable with an innovator product 407 
that is manufactured without a licence from the innovator company and marketed after the 408 
expiry date of the patent or other exclusive rights”.35 Generic medicines are identical to the 409 
original innovator product in terms of safety, quality, efficacy, dosage and dosage form, 410 
product strength and the administration route. Generic medicines are also utilised for the 411 
same use or indication as the original innovator product.
24,26,35
 Several studies note that 412 
generic medicines nearly always emerge with lower prices than originator products and thus 413 
have the capacity to reduce pharmaceutical expenditure, produce significant price savings, 414 
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allow subsidisation of additional medicines thus enhancing access to new medicines for 415 
patients.
13,24,26,35
 Hassali et al.
35
 explored what role generic medicines played in the health 416 
system of eight selected countries including Australia. The study reported that generic 417 
medicines were between 20% and 90% less expensive compared to the original innovator 418 
medicines.
35
 Furthermore, the study recognised that Australia, utilising referencing pricing, 419 
opened the PBS to generic medicines. Australia, in 2005 also implemented a 12.5% price 420 
reduction policy which indicated that the first new generic pharmaceutical for listing on the 421 
PBS must be priced at least 12.5% below the current lowest priced brand.
35
 In 2011 this was 422 
increased to 16% (36). Additionally, since 2008 pharmacists were paid to dispense cheaper 423 
brands, this was updated in the 6CPA and is known as the Premium Free Dispensing 424 
Incentive.
36
 In particular, when they dispense a substitutable, premium-free PBS medicine 425 
they receive a premium free dispensing incentive and equal to AUD $1.78.
35,36
  426 
Changes to the pricing system including these mandatory price reductions and disclosure all 427 
are estimated over the 2008/09 to 2017/18 period to save the Australian health system AU$ 428 
6.4 billion.
35
  429 
A study that reported the rate of Australian community pharmacist’s generic substitution and 430 
cost-savings achieved for patients, in addition to patient acceptance of generic medicines was 431 
conducted.
24
 Generics were recommended by pharmacists in 96% of the prescription items 432 
eligible for substitution in the study. It was also revealed that due to the substitution, patient 433 
medicines expenditure decreased by approximately 21%. The high rate of substitution was 434 
thought to link to Australia’s generic medicine substitution policy and the dispensing 435 
incentives implemented by the country.
24
 However, the patient declined the opportunity to 436 
switch to a generic medicine as offered in 21.5% of cases. This may reflect a patient 437 
perception of these medicines are inferior quality or brand loyalty.
24
 438 
New Zealand has several policies to support the listing and uptake of generic medicines. In 439 
particular, these policies centred on reference pricing, competitive tendering and creation of 440 
competition between manufacturers of generic medicines.
13
 In a study by Spinks and 441 
colleagues,
33
 the differences in prices paid for a select group of medicines found that New 442 
Zealand paid lower prices for generic products than Australia. It must be noted that the 443 
comparison was limited to the ten generic medicines in the study and there is not full 444 
transparency with the actual price in NZ. However, if this is taken at face-value, it is 445 
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speculated that Australia could achieve savings of AU ~$460 million by purchasing generics 446 
at the New Zealand price.
33
  447 
Many studies in this review recognise the differences in pricing of generic medicines to be 448 
the likely result of differences in governmental and institutional pricing policies between 449 
Australia and New Zealand.
3,4,12,13,24,26,33,35
    450 
Reimbursement 451 
The coverage and reimbursement of medicines has most often been considered by the 452 
literature as the single most important factor determining patient access to medicines in high 453 
income countries such as Australia and New Zealand.
3,4,5,10-13,19,20,28-30,33–35,37-43
 In particular, 454 
many medicines that are not subsidised by a third party are often unaffordable for individual 455 
patients and so access to these medicines will be extremely limited.
3,4,5,10-13,19,20,28-30,33–35,37-43
 456 
Furthermore, even in the case that medicines are reimbursed by the national government,
12,13
 457 
patient cost sharing schemes (in terms of patient co-payments or co-insurance) can still lead 458 
to inadequacies in medicines access for patients.
3,4,5,10-13,19,20,28-30,33–35,37-43
 The theme of 459 
reimbursement covers three major sub-themes including national Pharmaceutical Schedule & 460 
Health Technology Assessment, Patient Co-Payments and Managed Entry Agreements.  461 
National Pharmaceutical Schedule and Health Technology Assessment 462 
Both countries utilise ‘subsidised access processes’ whereby the assessment of value of a 463 
medicine (also known as its cost-effectiveness) is determined by the country’s health 464 
technology assessment body.
3,4,5
 In Australia, the subsidisation of medicines is achieved via a 465 
positive recommendation by PBAC and subsequent approval by the Minister of Health, the 466 
new medicine and indication(s) is then listed on the PBS.
4,5,12,15,27
 PBAC does not operate 467 
under a capped budget however an overall capped health budget; any medicine expected to 468 
exceed AU $20 million per year must be approved by Cabinet.
4,5,12,15,27
 In New Zealand, 469 
PHARMAC operates the national pharmaceutical schedule for subsidised medicines and lists 470 
new medicines, indications and medical devices on the national schedule for New Zealand. 471 
PHARMAC administers the schedule alone and the New Zealand government or judiciary 472 
cannot block any listing.
4,5,13,20,28
 PHARMAC operates within a defined funding envelope 473 
which allows a fixed budget for listing of new medicines each year.
4,5,13,20,28
  474 
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Both PBAC in Australia and PHARMAC in New Zealand utilise health technology 475 
assessment and economic evaluation in their decision making for the addition of (new) 476 
medicines to the national pharmaceutical schedule. PBAC consider efficacy, safety, cost-477 
effectiveness and budget impact and utilises several methods of economic analysis including 478 
cost utility/ effectiveness analysis and cost minimisation analysis (CUA/CEA and 479 
CMA).
4,5,12,15,27
 Between 2015 and 2016 the PBAC criteria was revised; the revised document 480 
is now available (version 5.0) and reflect the changes that have occurred regarding health 481 
technology assessment, however the key factors for decision making are essentially the same 482 
as they have been in past guidelines.
7 
  483 
PHARMAC has recently moved toward implementing a new set of criteria named the 484 
‘Factors for Consideration’ which includes need, health benefit, costs and savings and 485 
suitability and is available to view on their website.
4,5,13,20,28,44
 The Factors for Consideration 486 
are represented in a circular diagram. Within the four dimensions listed above there are also 487 
three levels; the impact to the person, the person’s family, whanau and wider society and also 488 
to the broader health system. The extent to which any one particular factor is relevant, if at 489 
all, and the influence of each factor is for PHARMAC to determine on each occasion within 490 
the context of its legal obligations,
4,5,13,20,28,44
  PHARMAC primarily utilise cost-utility 491 
analysis (CUA) in economic analyses.
4,5,13,20,28
 492 
Several studies in this review directly compared access to medicines between Australia and 493 
New Zealand, where access to medicines was defined as a positive listing on the national 494 
pharmaceutical schedule. Many studies have noted that the number of medicines subsidised 495 
in New Zealand was less than the number subsidised in Australia.
3,4,5,30,33,41
 The comparison 496 
of pharmaceutical prices by Wonder and Milne,
3
 revealed that, of 139 new medicines listed 497 
on the PBS in Australia, only 59 of these were listed on the New Zealand PHARMAC 498 
schedule. The study also recognised that marketing authorization and registration occurred 499 
sooner in Australia; 53 of the 59 medicines reimbursed in New Zealand were reimbursed in 500 
Australia first with a mean difference of 32.7 months.
3
 The study considers that the 501 
differences in access between countries may have been due to differences in the financial 502 
constraints of each agency,
1
 in addition to the Australia implementing a greater number of 503 
risk sharing agreements to manage financial risk and limit excess costs.
3 
 504 
Moodie et al.
23
provide an interesting insight into differences in access. Their paper discusses 505 
the effect of PHARMAC’s capped budget and notes that this cap results in extra time in 506 
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funding decisions needed to ensure value for money and an ability to forecast expenditure. 507 
Moreover, the paper discusses New Zealand’s hesitance to fund ‘me-too’ medicines without 508 
the presence of an obvious financial or clinical benefit.
23
  509 
Another study compared access to a select number of licensed and subsidized medicines 510 
including Australia and New Zealand.
30
 It was discovered that New Zealand subsidised the 511 
oldest and smallest number of medicines included in the analysis while Australia subsidised a 512 
greater number of medicines and these tended to be newer (567 entities and 30 innovative 513 
entities subsidised in the Australian PBS compared to 503 entities and 19 innovative entities 514 
subsidised by PHARMAC in New Zealand).
30
 However, in Australia, inequities in access to 515 
higher cost medicines were experienced between public and private hospitals. This occurred 516 
due to funding mismatch where a cap on the funding available for public hospitals and the 517 
lack of a cap on the PBS often led to a lack of funds for higher cost medicines in public 518 
hospitals compared to higher income private hospitals leading to differential access to these 519 
medicines between hospitals.
42
   520 
Patient Co-Payments 521 
Patient access to medicines is likely to be constrained by patient co-payments or coinsurance, 522 
particularly when these costs are considerable.
10,11,12,13
 Patient co-payments can have a 523 
negative impact upon the affordability and thus access to medicines, particularly affecting 524 
lower income patients.
25
 Medicine co-payments by patients in Australia are implemented 525 
under two categories for medicines on the PBS. The first, for ‘general’ patients are maximum 526 
co-payments of AU $38.30 while concession card holders (seniors, lower income holders and 527 
some ‘other’ groups) pay AU $6.20.5,11 New Zealand patients pay NZ$ 5 for prescription 528 
medicines subsidised by PHARMAC for all patients besides children less than 13 years 529 
which receive subsidised medicines free of charge.
5
 Both countries have in place 530 
‘catastrophic coverage’ which are policies that protect against the risk of excessive out of 531 
pocket expenditure by patients.
10,11
 In Australia safety net thresholds of AU $1457.70 for 532 
general patients and AU $372 for concessional patients are present while in New Zealand a 533 
maximum of 20 co-payments per family per year is required (NZ $100) before no co-534 
payment is required to access these medicines.
3,4,12,13,23,25
 Morgan et al.,
20
 a study that 535 
reviewed pharmaceutical policy structures and performance indicators for seven countries 536 
including Australia and New Zealand, that the co-payments encountered by ‘general’ patients 537 
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in Australia were high compared to other countries with national drug benefit programmes, 538 
particularly compared to New Zealand.  539 
One study recognised that following an increase in patient co-payments in Australia for 17 540 
selected medicine on the PBS, significant decreases in the volume of dispensed medicines for 541 
12 of the 17 categories occurred. This result suggests that increases in patient co-payments 542 
for medicines can significantly impact the ability of patients to afford and thus access these 543 
medicines.
45
  544 
Both Australia and New Zealand possess little government regulation for medicines not listed 545 
on the national schedule, thus manufacturers are able to set prices at market entry. This was 546 
often the case for high-cost medicines and orphan drugs leading to substantial patient co-547 
payments.
10,11,12,13,42
   548 
Managed Entry Agreements 549 
Managed entry agreements (MEA’s), also known as patient access or risk sharing schemes 550 
are utilised in both Australia and New Zealand; these are utilised as unconventional access 551 
agreements for medicines. These exist between third party (healthcare) payers and 552 
pharmaceutical companies for conditional coverage of specific medicines.
46,48
 These schemes 553 
allow coverage or reimbursement of medicines subject to specific conditions and address 554 
uncertainty regarding the likely efficacy of these medicines.
46-48
  555 
These managed entry agreements exist in three formats; outcome based, evidence generation 556 
and financial agreements. The first (outcome based) links the reimbursement of the medicine 557 
to clinical outcomes, measured with regard to patient quality or quantity of life. Evidence 558 
generation is utilised where a positive reimbursement decision is dependent upon the 559 
collection of additional evidence for the respective pharmaceutical.
46
 In the case of both of 560 
these access schemes, the prices of these medicines will be reduced if outcome targets are not 561 
met or the generation of additional evidence is not provided.
10
 The third type of MEA is the 562 
financially based schemes, which require company contributions to the cost of the particular 563 
pharmaceutical product i.e. through discounts, rebates, cost-capping, price-volume 564 
agreements or utilisation caps.
10,46
 A 2015 study,
46
 reviewed the number of patient access 565 
schemes in Australia and New Zealand amongst other countries, and found that 98 schemes 566 
were present in Australia and only 5 in New Zealand. All five managed entry agreements in 567 
New Zealand were financially based, whilst 41 of 74 schemes in Australia were hybrid 568 
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schemes that included both a financial and an outcome component. Three schemes in 569 
Australia were based upon evidence generation.
46
 A separate study,
47
 investigated the number 570 
of managed entry agreements in Australia and identified 71 MEA’s in use with 26 restricted 571 
to use in hospitals. Managed entry agreements were most often utilised to allow access to 572 
(higher cost or innovative) medicines for patients, that may not otherwise be funded based on 573 
health technology assessment (due to uncertainty regarding cost-effectiveness or budget 574 
impact).
10,46-48
   575 
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Discussion 576 
This review provides a systematic and comprehensive literature review between 2008 and 577 
2016 of pharmaceutical policies in Australia and New Zealand and how these policies may 578 
influence access to medicines in each country. It is vital to review this research in the context 579 
of the current policies of respective countries and therefore we have also provided a summary 580 
of pharmaceutical policies and practices in Australia and New Zealand and how the 581 
implementation of these policies may have influenced medicines access in each country.  582 
This review provides a novel consolidation of medicines access research, based on 583 
differences in policy, and therefore adds to the current literature on the topic. To date, to our 584 
knowledge, no other review has encompassed the effect on medicines access outcomes in this 585 
manner. The overarching goal was to provide a comprehensive review, to be used by policy 586 
decision-makers to better inform future policy reform. The review acknowledged 3 major 587 
levels of pharmaceutical policy with 9 subcategories. Differences in marketing authorization, 588 
medicine switch, orphan drug and pricing and reimbursement policies between the two 589 
countries were acknowledged to result in differential access to medicines.  590 
Australia and New Zealand have similar national health systems; Australia and New Zealand 591 
are primarily publicly funded health systems and each utilise a major national medicines 592 
policy. This medicines policy endeavours to provide access to medicines for patients ensuring 593 
medicine safety, quality and effectiveness at a reasonable cost. Cost is deemed one of the 594 
most important barriers to access of medicines by both countries.
4,5,6,12,13,20
 Pharmacies are 595 
recognised in both countries as a means to provide and improve access to medicines.
4,5,6,12,13
  596 
However, there are notable differences between the two countries. Marketing authorisation 597 
policies differ between the two countries. Whilst both countries have implemented a single 598 
national regulatory authority (TGA in Australia, Medsafe in New Zealand) and both consider 599 
the efficacy, safety and quality of medicines, Australia had implemented a parallel processing 600 
policy while New Zealand had not. This policy has enabled for the submission of medicine 601 
registration to be conducted at the same time as submission for medicine subsidisation on the 602 
national reimbursement list. This difference has led to significantly shorter time frames 603 
between regulatory submission to subsidised access in Australia compared to New 604 
Zealand.
3,4,5,10,12,13,15,20,29,30
 As mentioned earlier both countries were estimated to have a 605 
registration period of 52 weeks, Australia had a minimum time from regulatory submission to 606 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
24 
 
subsidised access of 72 weeks as opposed to 84 weeks in New Zealand. Additionally, a study 607 
of seven countries within the Asia pacific region (Australia, New Zealand, China, Japan, 608 
Korea, Taiwan and Thailand) by Cook et al.,
5
 critical differences were seen in time taken 609 
from regulatory submission to subsidised access to medicines. Moving forward, having a 610 
separate and parallel system that evaluates medicine registration and subsidisation may be 611 
one way of shortening this time and thus improve access.  612 
  613 
Reclassification of medicines from prescription to non-prescription was found to be more 614 
common in New Zealand due to a variety of factors, most notably the national confidence in 615 
pharmacists, consumers and Medsafe. Political rigidity in Australia has been reported to limit 616 
medicine ‘switch’.6,19 ‘Switch’ utilised in a responsible and safe manner was recognised to 617 
promote patient-centred care and thus had the capacity to improve patient access to 618 
medicines.
6,19
 Reclassification in community pharmacy has been reported to impact 619 
accessibility of medicines in nine European countries, as post-deregulation there was an 620 
associated increase in pharmacy establishment.
34
 However, this study also noted that this 621 
tended to be in urban areas. Therefore, whilst reclassification may increase access, policy 622 
makers in Australia and NZ should also bear in mind equitable access – as described by 623 
Vogler and colleagues.
34
  624 
Orphan drug legislation was implemented in Australia, in contrast New Zealand does not 625 
have such as legislation, except for a NZ $5 million fund for high cost medicines for rare 626 
disorders.
10,11
 The use of this legislation in Australia promoted the availability of, and access 627 
to, orphan drugs in the country. No study quantitatively compared access to orphan drugs 628 
between Australia and New Zealand, however, due to variances in pharmaceutical policy 629 
relevant to these medicines differences in access may exist. Future research is warranted in 630 
this area. Managed entry agreements were innovative access schemes to encourage and allow 631 
access to medicines that lacked sufficient evidence for reimbursement or to allow access to 632 
high cost medicines including orphan drugs. Australia implemented a much larger number of 633 
managed entry agreements compared to other countries (including New Zealand).
46-48
  634 
Higher prices of medicines often limit patient access twofold; higher prices reduce the 635 
likelihood of a listing on the national reimbursement schedule, as well as increased out-of-636 
pocket costs for patients for non-subsidised, often higher cost, medicines. Both countries 637 
utilised different pricing policies -- reference and value based pricing. Medicine prices in 638 
New Zealand were acknowledged to be consistently lower than those prices in Australia, 639 
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especially with regard to generic medicines.
13,20,21,33,34
 Effective use of competition, a 640 
competitive tendering process and particularly, the use of a fixed, capped budget by 641 
PHARMAC in New Zealand were considered important factors in the success of PHARMAC 642 
in negotiating these lower prices, when compared to the prices of medicines in 643 
Australia.
3,4,5,13,20,21,24,26,33-35
 Currently, in Australia the DOH is responsible for negotiating 644 
prices of pharmaceuticals with the manufacturer; competition between pharmaceutical 645 
manufacturers and competitive tendering are unlikely to be successful for generic 646 
medications as multiple generics of the same medicine are available on the PBS.  647 
Both countries use similar criteria for the selection of medicines for reimbursement, i.e. 648 
health technology assessment is used by PBAC and PHARMAC.
3,4,5,30,33,41
 Listing on the 649 
reimbursement schedule of medicines is undoubtedly the most important factor determining 650 
patient access to medicines. However, although  the use of a fixed, capped, budget in New 651 
Zealand by PHARMAC has ultimately kept pharmaceutical spending down, it has been 652 
linked to the considerably lower number of medicines reimbursed in New Zealand compared 653 
to Australia.  This has led to many patients having to pay out-of-pocket for treatment, if 654 
available privately. NZ medicines policy has enlisted a number of avenues to access 655 
medicines that are not available on the listed schedule. On the other hand, higher co-656 
payments for patients can also pose a significant barrier to medicine access, regardless of the 657 
availability of medicines. This review recognised that Australia had much higher patient co-658 
payments for medicines at almost 8 times the payments required for patients in New Zealand. 659 
Australia does however have in place lower co-payments for concession card holders, which 660 
include elderly, lower income, eligible veterans. In both countries, those patients that exceed 661 
a specified threshold of spending on schedule-listed medicines are in place to prevent 662 
excessive out of pocket costs for patients. The limit for ‘general’ Australian patients was 663 
approximately 13 times the limit compared to New Zealand patients, and for concession card 664 
holders in Australia was around 3 times higher than that for New Zealand 665 
patients.
4,5,10,11,12,13,23,25,30,37
 When compared to overseas, New Zealand has one of the “most 666 
generous prescription charge regimes in the world” (beehive); the United Kingdom 667 
prescription charges are equivalent of approximately 1/3 of that of Australia, Canada’s costs 668 
vary by province but often is based on household income. Pressure on pharmacies with the 669 
reduced income led to many pharmacies charging additional fees, for example after-hours 670 
fees, which then were passed on to the patient. This is one avenue that can be considered 671 
outside of New Zealand to reduce overall spending. Taken together, both countries exhibit 672 
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different policies that may act as barriers to access of medicines. Whilst NZ has much more 673 
restricted breadth of medicines that are listed on the schedule, Australian patients out-of-674 
pocket costs are generally much higher, which could impact also on access.  675 
Our definition of access to medicines included the availability in addition to financial and 676 
physical ability to obtain and receive relevant care involving the respective medicine(s). 677 
Australia and New Zealand both illustrate complex, highly efficient and functioning 678 
pharmaceutical systems which appear to both promote in some cases, but restrict access to 679 
medicines in others. Australia appears to have in place several policies, most notably parallel 680 
processing which enhances medicine availability in a manner that is not replicated in many 681 
other health systems around the globe. As mentioned, this could be something that policy 682 
decision-makers (including those in New Zealand) consider to reduce the time between 683 
registration to review for reimbursement.  684 
At a higher level, the themes and sub-themes that were identified in this review have the 685 
potential to influence future frameworks for policy analysis. In 2013, Bigdeli and 686 
colleagues,
50
 reviewed access to medicines from a health system perspective; they 687 
acknowledged that the access to medicines barriers are: “complex and interconnected”. In 688 
addition, they believe that the existing frameworks only partly take into account the full range 689 
of barriers. The authors of the review suggested a shift from the existing frameworks 690 
available to take into consideration these complex interactions and barriers. We believe that 691 
our review adds to this model or a future reformed model; we must consider the patient 692 
outcomes at the centre of the policy framework – as Bigdeli has – and also ensure that we 693 
consider avenues for access of new and emerging medicines, including those that lack enough 694 
evidence to be fully subsidised through a national listed-schedule.
50
 We must also look to 695 
other countries for novel and innovative schemes to reduce the cost of medicines, especially 696 
with projected increases in healthcare costs in the future, and look how these may work on a 697 
holistic level – for the patient and in the national context. Laterally, this review also 698 
highlights the potential role of the pharmacy profession in medicines access; deregulation is 699 
one example, in some European countries this has increased access of medicines to the 700 
public, by increasing the number of pharmacies that have been established.  701 
 702 
Whilst this review highlights many themes for consideration to potential policy decision-703 
makers, there are several limitations. Firstly, bias in terms of publication and outcome 704 
reporting bias may have led to publication or non-publication of articles depending on the 705 
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nature or direction of the finding of which we cannot account for.
9
 We also need to bear in 706 
mind bias could be included from articles that had associations with organisations, i.e. that 707 
were written by consultants to the industry. Articles were only included if an English 708 
language version was available; if a publication was in another language alone, it was 709 
excluded. With consideration of these limitations, our review provides important insights into 710 
pharmaceutical policy in Australia and New Zealand and its impact upon patient access to 711 
medicines in each country.   712 
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Conclusion 713 
A variety of pharmaceutical policies have been reported in this review, which illustrate the 714 
similarities and differences between Australia and New Zealand, in reference to policies that 715 
affect medicines access. Key differences between the two countries include differences in 716 
marketing authorization and medicines registration policies with Australia implementing 717 
parallel processing policies to enhance the time from regulatory submission to subsidised 718 
access in the country. Australia appears to cover and reimburse a greater number of 719 
medicines while New Zealand achieves much lower prices for medicines than their 720 
Australian counterparts and has been more successful in controlling national pharmaceutical 721 
expenditure. Delays in patient access to new therapies in New Zealand have considerable 722 
implications for overall patient access to medicines, however, higher patient co-payments and 723 
relative pharmaceutical expenditure in Australia and its effect upon patient access to 724 
medicines must also be considered.  725 
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Table 1. Study inclusion & exclusion criteria. 733 
No    Category  Inclusion Criteria 
1 Year of release 2008-2016  
2      Publication 
Type 
Full text articles in peer-reviewed scientific journals and in English 
3      Countries 
Covered 
Australia and New Zealand  
4 Kinds of 
Medicines 
Brand name drugs  
5    Definition and 
issues to 
include 
Medicines, access, (specialised) clinicians, biologicals, (patient) 
access, policy & regulation.  
 Definitions of pharmaceuticals / medicines 
 (Patient) access, drug availability or accessibility 
 Marketing authorization, approval processes 
 Legislation, policy, regulation 
 Licensing, pricing, funding,  health technology assessment, 
reimbursement 
 Other relevant legislation/access factors 
6    Methodology 
and topic of 
research 
Review of peer reviewed journal articles investigating political and 
regulatory mechanisms in Australia and New Zealand by which 
medicines are accessed, funded and reimbursed and the mechanisms 
that define these aspects of pharmaceutical policy and medicine 
access.  
 
7   Outcomes of 
regulation or 
policy 
Pharmaceutical policies in New Zealand and Australia that facilitate 
or hinder (patient) access, funding and reimbursement of medicines 
in either country.  
 
8. Bias No presence of issues in study design, methods, data collection, 
analysis or any other factor of the study or article that could lead to 
bias of the individual study. 
 Exclusion Criteria 
1 Articles that are not published in the English Language  
2 News Reports 
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Table 2 Themes and sub-themes extracted from the included literature. 734 
  735 
Themes  Sub-Themes 
National Health 
System 
 National Health Policy 
 Pharmacy System 
 Marketing Authorization and 
Regulation 
 Prescription to Non-Prescription 
Medicine Switch 
 Orphan Drug Policies 
Pricing  
 Generic Medicine Substitution 
 
Reimbursement 
 National Pharmaceutical Schedule & 
Health Technology Assessment 
 Patient Co-Payments 
 Managed Entry Agreements 
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Table 3:  An overview of pharmaceutical policies influencing access to medicines and their implementation in Australia and New Zealand.  736 
 737 
Country 
Covered  
National Health Policy – 
Overview (Reference) 
Pharmacy 
System  (Ref) 
Marketing 
Authorization and 
Regulation – 
Overview and 
Timing, 
Parallel Processing 
(Y/N) 
(Ref) 
Prescriptio
n to Non 
Prescriptio
n Medicine 
Switch 
(Ref) 
Orphan 
Drug 
Policies 
(Ref) 
Pricing (Ref) Generic 
Medicine 
Substitution 
– Policies 
and 
Incentives 
 (Ref) 
Patient Co-
payments- 
Extent and 
Policies(Ref) 
Reimbursement  
1. Procedures and/or 
coverage 
2. HTA Criteria 
Australia 
(AUS) 
 
National Public Health System 
with a mix of public and 
private funding 
The national (commonwealth) 
government funds two thirds 
of total healthcare spending 
while the other third is funded 
by other, lower levels of 
national and state 
government.  
Patient out of pocket 
expenditure accounts for 17% 
of total expenditure on health 
care 
National Medicines Policy 
provides the framework for the 
regulation and funding of 
medicines in AUS.  
(4 ,5, 12) 
Over 6, 663 
pharmacies and 
chemists 
distributed across 
AUS.  
Pharmacies and 
their ownership are 
governed by state 
and federal 
legislation.  
Pharmacy 
ownership 
restricted (in large 
part) to registered 
pharmacists 
Majority owned by 
pharmacists with a 
small number 
owned by non-
profit entities. 
Pharmacies also 
provide a range of 
other, usually 
primary health care 
services including 
preventative care 
and medication 
management. (12, 
15) 
Applications for 
registration and 
marketing of new 
medicines conducted 
by the Australian 
Therapeutic Goods 
Administration (TGA).  
Submission to the TGA 
for medicine 
registration can be 
conducted alongside 
submission to the 
pharmaceutical 
Benefits Advisory 
Committee (PBAC) 
who operate the 
pharmaceutical benefits 
scheme (PBS) in AUS.  
Standard registration 
process takes 52 
weeks (12 months) 
Minimum time from 
regulatory submission 
to subsidised access = 
72 weeks 
(Y) 
(3, 5 ,12, 15) 
AUS has four 
categories of 
medicines; 
prescription, 
general sales, 
pharmacy 
only, and 
pharmacist 
only.  
AUS does not 
have an 
overall 
governmental 
position on 
medicine 
switch.  
The Secretary 
to the 
Department of 
Health or their 
respective 
delegates 
makes the 
final decision 
on switch.  
(6, 19) 
Yes – 
Australia’s 
national 
orphan drug 
policy and 
under 
consideration 
within 
Australia’s life-
saving drug’s 
programme 
(10, 11) 
Fixed - 
Reference and 
value based 
pricing  
No 
governmental 
price regulation 
of medicines not 
on the national 
schedule 
(10, 12, 20-22) 
Brand Premium 
Policy-  
Reference 
pricing system 
where the 
government 
subsidises only 
up to the price of 
the lowest price 
brand 
Generic 
Substitution 
Policy-   Allows 
community 
pharmacists to 
voluntarily 
substitute 
specified PBS-
listed named 
medicines with 
the equivalent 
generic 
medicine 
(12, 24- 26) 
General patient 
co-payments are 
AU $37.70 (US 
$29.39) 
Concession card 
holders AU 
$6.10 (US $ 
4.76) 
 
Safety Net 
Thresholds of 
AU $1421.20 for 
general patients 
and AU $360 for 
concessional 
patients – Once 
threshold is 
reached, 
patients receive 
all remaining 
prescriptions 
free for that 
(financial) year 
(5, 11, 12, 25) 
 
1. The subsidisation of 
medicines is managed by the 
AUS department of health with 
advice provided by the 
Pharmaceutical Benefits 
Advisory Committee (PBAC). 
This combination lists new 
medicines and indications on 
the pharmaceutical benefits 
schedule (PBS) which is the 
national pharmaceutical 
schedule of subsidised 
medicines for the country. 
PBAC does not operate under 
a capped budget however any 
medicine expected to exceed 
AU $20 million per year must 
be approved by Cabinet.  
 
2. PBAC considers efficacy, 
safety, cost-effectiveness and 
budget impact. Overall this 
makes up a proportion of a 
capped health budget. 
Economic analysis methods 
utilised included cost utility/ 
effectiveness analysis and 
cost minimisation analysis 
(CUA/CEA and CMA) 
(4, 5, 12, 15, 27) 
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Country 
Covered  
National Health Policy – 
Overview (Reference) 
Pharmacy 
System  (Ref) 
Marketing 
Authorization and 
Regulation – 
Overview and 
Timing, 
Parallel Processing 
(Y/N) 
(Ref) 
Prescriptio
n to Non 
Prescriptio
n Medicine 
Switch 
(Ref) 
Orphan 
Drug 
Policies 
(Ref) 
Pricing (Ref) Generic 
Medicine 
Substitution 
– Policies 
and 
Incentives 
 (Ref) 
Patient Co-
payments- 
Extent and 
Policies(Ref) 
Reimbursement  
1. Procedures and/or 
coverage 
2. HTA Criteria 
New 
Zealand  
(NZL) 
National Public Health System 
with a mix of public and 
private funding 
80% of NZL expenditure on 
health care is publically 
funded. 
20 District Health Boards 
across NZL are responsible 
for public health services for 
their respective populations 
 (4, 5, 13) 
Approximately  
1000 pharmacies 
distributed across 
New Zealand. 
Pharmacies must 
hold a license 
under the 
Medicines Act 
1981 that allows 
operation if a NZL 
registered 
pharmacist is 
present, 
Pharmacies may 
be owner by a sole 
individual, 
partnership or 
company however 
the majority share 
must be held by a 
single or group of 
NZL registered 
pharmacists.  
Pharmacies are 
also involved in 
primary health care 
services under 
contract of DHBs. 
(13) 
The New Zealand 
Medicines and Medical 
Devices Safety 
Authority (Medsafe) is 
responsible for 
applications for 
registration and 
marketing of new 
medicines in NZL.  
Positive 
recommendation by 
Medsafe is required 
before submission to 
PHARMAC for a 
decision on inclusion 
on the national 
pharmaceutical 
schedule.   
Standard registration 
process takes 52 
weeks (12 months) 
Minimum time from 
regulatory submission 
to subsidised access = 
84 weeks 
(N) 
(3, 5, 13)  
NZL has four 
categories of 
medicines; 
prescription, 
general sales, 
pharmacy 
only, and 
pharmacist 
only. 
The Medicines 
Classification 
Committee 
(MCC), 
operates a 
Ministerial 
advisory 
committee, 
recommends 
classifications 
of medicines 
to one of the 
four 
categories of 
medicine and 
is operated by 
Medsafe in 
NZL.  
(6, 19) 
No overall 
policy 
PHARMAC do 
possess a $5 
million orphan 
drugs fund for 
inclusion of 
orphan 
medicines on 
the national 
pharmaceutic
al schedule 
(10, 11) 
Fixed - 
Reference 
Pricing, 
competitive 
tendering, price 
negotiations for 
medicines on the 
national 
reimbursement 
schedule  
No 
governmental 
price regulation 
of medicines not 
on the national 
schedule 
(13, 23) 
Competitive 
tendering 
between generic 
manufacturers 
based upon 
reference pricing  
Switch to 
generic 
medicines as 
medicines come 
off patent (re-
tendering) 
(13) 
NZ$ 5 (US 
$3.76) for all 
patients besides 
Children under 
13 years which 
receive 
subsidised 
medicines free 
of charge.  
(5, 13, 20) 
1. The New Zealand 
Pharmaceutical Management 
Agency (PHARMAC) operates 
the national pharmaceutical 
schedule for subsidised 
medicines and lists new 
medicines, indications and 
medical devices on the 
national schedule. PHARMAC 
administers the schedule 
alone and the NZL 
government or judiciary 
cannot block any listing.    
PHARMAC operates within a 
defined funding envelope 
which allows a fixed budget for 
listing of new medicines each 
year.  
2. PHARMAC currently 
considers nine ‘decision’ 
criteria upon which funding 
decision are made, these 
criteria include cost-
effectiveness, budget impact, 
efficacy, safety and other 
relevant political factors.  
PHARMAC primarily utilise 
cost-utility analysis (CUA) in 
economic analyses. 
(4, 5, 13, 20, 28)    
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Highlights 
 
• This review has identified key areas of difference in medicines policy between 
Australia and NZ which potentially could influence patient access to medicines; and 
drug prices and reimbursement status in each country 
• Australia and New Zealand differed in terms of marketing authorization and 
regulation with parallel processing available in Australia, enhanced medicine switch 
in New Zealand and a lack of orphan drug legislation in New Zealand.  
• New Zealand achieved much lower prices for medicines and required lower patient 
co-payments and has been more successful in controlling national pharmaceutical 
expenditure while Australia appeared to fund a greater number of medicines on 
their national pharmaceutical schedule.  
 
• Delays in patient access to new therapies in New Zealand have considerable 
implications for overall patient access to medicines, however, higher patient co-
payments and relative pharmaceutical expenditure in Australia and its effect upon 
patient access to medicines must also be considered.  
 
• This critical anaysis allows for the evaluation of policies that affect patient access to 
medicines and thus could potentially better inform policy decision-makers moving 
forward when considering access to medicines. 
